Our 6 ‘Best Buys Now’ Shares “This Stock Could Be Like Buying Amazon in 1997” Image source: Getty Images. Paul Summers owns shares in VanEck Vectors Video Gaming and eSports UCITS ETF. The Motley Fool UK owns shares of and has recommended Activision Blizzard. The Motley Fool UK has recommended Frontier Developments and recommends the following options: long January 2022 $75 calls on Activision Blizzard and short January 2022 $75 puts on Activision Blizzard. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. To say that eSports (or ‘competitive gaming’) has been growing in popularity is putting it mildly. According to the Newzoo Global eSports Market Report, revenue growth from the industry has increased by an average of 28% yearly since 2015. Thanks to the coronavirus, this purple patch looks set to continue. eSports: here to stayYou probably don’t need me to tell you that the lockdowns in 2020 have been hugely beneficial to raising the profile of gaming and eSports. With nowhere to go, huge swathes of people (re)discovered their inner gamer to pass the time and make new, digital contacts. If they weren’t playing themselves, they were watching other people do so via streaming service Twitch.5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…And if you click here we’ll show you something that could be key to unlocking 5G’s full potential…This rapid acceptance and adoption should mean the gaming-related boom keeps going even when the pandemic is over. It’s already been estimated that the global eSports audience will hit 495 million people in 2020.Other developments that highlight eSports’ growing profile include the involvement of bookmakers. With no opportunities for punters to gamble on ‘traditional’ sports, firms such as William Hill have been taking bets on the outcomes of gaming matches.Another sign of the times was the launch of talent development company Guild Esports in June. Co-owned by David Beckham, its goal is to find and nurture the next generation of professional players. While certainly not guaranteed to succeed, Beckham joins a growing list of sports stars such as Michael Jordan and Mike Tyson making investments in the video gaming industry. Here’s how you can join them.How to investThe most direct route into gaming as an investor is to buy a developer. UK-listed candidates include Codemasters, Frontier Developments and Team 17. Another option is ‘picks and shovels’ company Keywords Studios. It specialises in providing a variety of services to the video games industry. All of the above appear to be decent businesses with solid futures. The problem, however, is that most trade on frothy valuations due to the recent post-crash buying frenzy seen in the market.Keywords-excluded, owning shares in a single, gaming-related company can also be risky. Much like a movie studio, a lot of money may rest on a new title living up to the hype. Should it not, some holders won’t hesitate to dump their stock.Personally, I’m taking a different route.My preferred pickThe VanEck Vectors Video Gaming and eSports UCITS ETF launched just over one year ago. Tracking the MVIS Global Video Gaming and eSports Index, it gives exposure to 25 companies. Importantly, all of these generate more than 50% of their revenue from the industry. Portfolio holdings include giants such as Nintendo and Tencent. Developer Activision Blizzard also features, as does Electronic Arts.Based on performance so far, the 0.55% ongoing fee certainly doesn’t seem excessive. From inception (24 June 2019) to the end of July 2020, the fund’s net asset value climbed an astonishing 63%!Buyer bewareOf course, no investment is a nailed-on home run. There will be setbacks along the way, perhaps in the form of increased regulation. The threat posed by cybercriminals shouldn’t be easily dismissed either. With a young, global, increasingly-affluent audience and new consoles (Playstation 5 and Xbox Series X) coming soon, however, the outlook for this coronavirus-proof industry looks rosy. In fact, I think gaming/esports could prove to be one of the best investment themes of the decade. Enter Your Email Address Paul Summers | Sunday, 30th August, 2020 I think eSports could make investors filthy rich. Here’s how I’m playing it I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement. Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we’re offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our ‘no quibbles’ 30-day subscription fee refund guarantee. Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge! Simply click below to discover how you can take advantage of this. I’m sure you’ll agree that’s quite the statement from Motley Fool Co-Founder Tom Gardner.But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.What’s more, we firmly believe there’s still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.And right now, we’re giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool. See all posts by Paul Summers
PAGE TURNERS The Anatomy of Fear You have entered an incorrect email address! Please enter your email address here Share on Facebook Tweet on Twitter Free webinar for job seekers on best interview answers, hosted by Goodwill June 11 Please enter your name here LEAVE A REPLY Cancel reply Support conservation and fish with NEW Florida specialty license plate TAGSBest SellersBiblesBooksPandemicThe Hustle Previous articleWhat do you need to know about pet insurance?Next articleWhere God is, there is singing Denise Connell RELATED ARTICLESMORE FROM AUTHOR The hottest book in town right now is the Holy Bible. Over the last month, Tyndale House Publishers — one of several companies that sells Bibles and other religious texts — has seen 44% and 60% jumps in 2 of its major Bible editions.An executive told the Christian Post that this isn’t the first time people have turned to the company in a crisis: Business also boomed after 9/11.The publishing industry is stuck on a cliffhangerWith bookstores shuttering, festivals canceled, and major book releases postponed, publishers are feeling the crunch. Adult fiction dropped 21%, according to Forbes, with genre novels taking the biggest hint:Epic fantasy fell 25%.Crime thrillers sunk 24%.COVID-19 is reshuffling popular literature as we know it, and — religious texts aside — there are a few big winners.Parents across the country are giving Brain Quest workbooks to their kids, and sales of children’s nonfiction were up almost 40% at one point in mid-March. One micropress — Modern Kid Press, run by a Texas couple — has 5 workbooks on Amazon’s Top 100 overall bestseller list.Pestilence lit is the new crime novelThe other alphas of the new publishing industry: All those classic novels that you promised yourself you would get around to reading one day, like One Hundred Years of Solitude, and — of course — pandemic fiction.This March, The Plague by Albert Camus and Station Eleven by Emily St. John Mandel each saw double to triple increases in sales, raising the ultimate question — why settle for escapism when you can drown your fears in the most dystopian version of reality? From The Hustle Please enter your comment! Save my name, email, and website in this browser for the next time I comment.
ShareFacebookTwitterPinterestWhatsappMailOrhttps://www.archdaily.com/236500/residencial-commercial-building-in-azzate-park-associati Clipboard “COPY” CopyAbout this officePark AssociatiOfficeFollowProductsWoodConcrete#TagsProjectsBuilt ProjectsSelected ProjectsResidential ArchitectureHousingApartmentsCommercial ArchitectureAzzateHousingMixed UseItalyPublished on May 23, 2012Cite: “Residencial-Commercial Building In Azzate / Park Associati” 23 May 2012. ArchDaily. Accessed 11 Jun 2021.
“COPY” Area: 120 m² Year Completion year of this architecture project Photographs: BoysPlayNice Manufacturers Brands with products used in this architecture project Architects: smlxl Area Area of this architecture project Loft 5.04 / smlxl Loft 5.04 / smlxlSave this projectSaveLoft 5.04 / smlxl Year: “COPY” ShareFacebookTwitterPinterestWhatsappMailOrhttps://www.archdaily.com/805862/loft-4-smlxl Clipboard CopyAbout this officesmlxlOfficeFollowProductConcrete#TagsProjectsBuilt ProjectsSelected ProjectsResidential ArchitectureHousingApartmentsPragueCzech RepublicPublished on March 14, 2018Cite: ” Loft 5.04 / smlxl” 14 Mar 2018. ArchDaily. Accessed 11 Jun 2021.
Portland, Ore.In November, three Oregon prisons — Two Rivers, Salem, and Snake River — reported the state’s highest rate of workplace COVID-19 infections.Oregon prison laundry, 2017.By Oregon law, prisons are workplaces. All prisoners are forced to work a 40-hour week. On Nov. 23, Snake River reported 518 infections among workers, and 157 among guards and staff.Last year, imprisoned workers, who on average earn pennies an hour, made $28 million for Oregon Corrections Enterprises. OCE employs thousands of workers in 10 prisons, including laundries. These workers process 40,000 pounds, or 20 tons, of laundry for at least 33 hospitals each day, every day, including laundry of COVID-19 intensive care wards. They earn on average one dollar a day.In April, Michael Zell, a prisoner at Salem, wrote that OCE bosses illegally removed biohazard labels from COVID-19-infected laundry before workers handled it. Suspecting that this illegal practice was taking place in all OCE laundries, Zell warned that the coronavirus, already raging in prisons, would increase.Soon after, Two Rivers prison, the site of an OCE laundry with 168 workers, reported 40 new infections. Jason Ellis, a prisoner at Two Rivers, said that in spite of the spike in COVID-19 infections, laundry workers have to report for work. This was confirmed by a prison spokesperson. (streetroots.org)The U.S. Occupational Safety and Health Administration (OSHA) regulates prison laundries, workshops, factories, call centers, and other work spaces, as well as the working conditions for those who labor in them. The U.S. Center for Disease Control provides COVID-19 protocols for workplaces, including those in prisons. These U.S. government agencies recognize that prisoners are workers, and, as all workers, have the right to health and safety on the job. As it is for all workers, though, enforcement is another matter.For example, Oregon Corrections Enterprises posted a notice online and in its prison laundries that “all employees and adults in custody (AICs) working in OCE laundry follow standard/universal precautions as defined by both OSHA and CDC, to wear appropriate personal protective equipment.”However, the National Lawyers Guild states that this contradicts reality; that workers in Oregon prisons handling COVID-19-infected hospital laundry are not provided PPE, neither gloves nor masks. That, in fact, face coverings OCE provides are not PPE, but “utility masks, made of 100% cotton,” and produced by OCE garment workers.Of the thousands of workers employed in OCE’s prison workshops, about 1,500 are highly skilled and work as upholsterers, welders, ironworkers, metal fabricators, carpenters, sewing machine operators, fabric pattern cutters, cabinetmakers and woodworkers, painters, and more. These workers are “paid” $7.25 an hour, the federal minimum wage (the Oregon minimum wage is $11.25), but they actually “take home” on average only $82 a month. The rest of their wage is taken by the state – to pay for their own imprisonment.FacebookTwitterWhatsAppEmailPrintMoreShare thisFacebookTwitterWhatsAppEmailPrintMoreShare this
News RSF denounces Malaysia’s harassment of Al Jazeera journalists News QatarMiddle East – North Africa Organisation to go further “We are appalled at this sentence and at the prospect that it might be carried out,” said Reporters Without Borders secretary-general Robert Ménard. “Without going into the details of the charges against him, we note that his trial took place amid very tense relations between Jordan and Qatar, which meant it was not held calmly.”The broadcast on 6 August by the Qatar-based TV station Al-Jazeera of a very critical programme about Jordan triggered the immediate cancellation of the work permits of the station’s journalists and the closure of its office in Amman. The Jordanian authorities accused the station of subversion and insulting the royal family and the national media strongly criticised Qatar.Majali, who worked for Al-Jazeera, was arrested in the Qatari capital, Doha, in February and his trial began in May. His lawyer now has 15 days to appeal against the decision. Al-Jazeera said Majali was accused of spying for Jordan, but the lawyer simply said it was for “a foreign country.” October 24, 2002 – Updated on January 20, 2016 Journalist condemned to death for “spying” News Change to “fake news” law poses new threat to Qatar’s journalists January 23, 2020 Find out more August 7, 2020 Find out more RSF_en Unacceptable call for Al Jazeera’s closure in Gulf crisis Follow the news on Qatar Reporters Without Borders today denounced the Qatar supreme court for sentencing a Jordanian journalist, Firas Majali, to death on 22 October for alleged espionage. QatarMiddle East – North Africa Receive email alerts News Help by sharing this information June 28, 2017 Find out more
Monica McElvaney, Detective Sergeant Gerry Staunton, Inspector Marianne Cusack, Denise Dunne, Garda Natasha Walsh, Chief Superintendent Ger Roche, Sergeant Louise English, and Superintendent Brian Sugrue at the launch of the new strategy. Photo: Brian ArthurLIMERICK Garda management has increased local resources to help victims of domestic violence and prevent potential cases of femicide.236 women died violently in Ireland between 1996 and 2020, including three so far this year, according to statistics published by Women’s Aid.It shows that 55 per cent of them were killed by a partner or ex-partner, and 62 per cent died in their own homes.18 children died alongside their mothers over the last 24 years.Almost nine in ten murdered women knew their killer, and, the most common method of killing was by stabbing with knives or other sharp objects.Of the 22 Irish murder suicides recorded since 1996, where women were killed by a male relative, 18 women were killed by their sons.Women’s Aid said: “We record these killings to illustrate the danger posed to women and to better understand how to increase protection of women and children.”“Our aim is to continue to try and break the pattern of male violence against women in the hope of preventing any further loss of life.”It said that femicide is broadly understood as men killing women and girls – precisely because they are women and girls.“Femicide is both a cause and a result of gender inequality and discrimination, both of which are root causes of all violence against women,” Women’s Aid went on.Operation Faoiseamh, was launched by Gardaí last April as part of the force’s community engagement response to Covid-19, “aiming to prevent loss of life and to ensure that victims of domestic abuse were supported and protected during this extraordinary time”.Gardaí said they have recorded a 25 per cent year-on-year increase in calls for assistance in respect of Domestic related issues between 2019 and 2020.In support of Operation Faoiseamh, Gardaí in the Limerick Division have launched a local initiative aimed at providing additional support, guidance and advice to those seriously at risk from domestic violence.This includes both physical violence and coercive control which in effect is the emotional and psychological control of victims by the perpetrators of domestic violence.Sign up for the weekly Limerick Post newsletter Sign Up Limerick Chief Superintendent Gerry Roche said he had committed two trained members of An Garda Síochána to identify, engage with and positively interact with people at serious risk.He said this would involve a completely confidential and victim centric interaction with the victim’s best interests always in mind.Limerick Gardaí have also teamed up with ADAPT domestic abuse services in Limerick in supporting the nationwide 16 days of action for victims of domestic violence.As part of the global campaign Henry Street Garda station, like other buildings, is being illuminated in the colour purple for the duration of the 16 days of action.Gardai said frontline officers, the Garda National Protective Services Bureau (GNPSB) and Divisional Protective Service Units (DPSU) were all resourced and available to respond to such crimes.“Currently there are 245 members and staff allocated to the GNPSB and 16 DPSUs nationally to investigate sexual and domestic crimes,” said a spokesperson.Women’s Aid said: “Domestic violence kills women. The types of abuse and behaviour that precedes intimate partner femicide mirrors what we hear from women each day on our 24-hour National Freephone Helpline 1800 341 900 and our one-to-one support services.”“We know just how dangerous domestic abuse can be and that, unfortunately, the horrendous catalogue of incidents that women disclose to us everyday are just the tip of the iceberg.““More public awareness of the signs, signals and patterns that lead to femicide is needed”. Advertisement Facebook Email Twitter NewsCrime & CourtExtra Garda resources to deal with domestic violenceBy David Raleigh – December 3, 2020 195 WhatsApp Previous article#PantoReturns: €400,000 gives Jack’s axe an extra edgeNext article#ThrowbackThursday: This week’s look back at our Out & About photos David Raleigh Print Linkedin
WhatsApp TAGS Pinterest Ultra-Orthodox Londoners roll up sleeves to fight COVID Facebook Facebook Pinterest Previous articleTourney director on planning Slam in pandemic: ‘relentless’Next articleStairway to heaven: Skiers scale 223 steps to downhill start Digital AIM Web Support WhatsApp Two men from the Haredi Orthodox Jewish community arrive at an event to encourage vaccine uptake in the ultra-Orthodox community at the John Scott Vaccination Centre in London, Saturday, Feb. 13, 2021. In hopes of breaking down barriers that sometimes isolate the Orthodox from wider society, community leaders organized the pop-up vaccination event for Saturday night to coincide with the end of Shabbat, the Jewish day of rest. By Digital AIM Web Support – February 14, 2021 Twitter Local NewsWorld News Twitter
WhatsApp Local NewsBusiness Twitter Pinterest By Digital AIM Web Support – March 23, 2021 Facebook AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial TAGS CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb 8, 2021– AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced a 100% reduction, or complete clearance, of toxic substrate in the kidney biopsy of the first patient dosed with the plato® gene therapy platform in the ongoing Phase 2 FAB-GT i clinical trial of AVR-RD-01, an investigational ex vivo lentiviral gene therapy for Fabry disease. Kidney substrate reduction is the trial’s primary efficacy endpoint and has previously been used by the U.S. Food and Drug Administration (FDA) in evaluating and approving treatments for Fabry disease. The company also announced six-month data from the first patient dosed in the Phase 1/2 trial of AVR-RD-02, an investigational ex vivo lentiviral gene therapy for Gaucher disease type 1, showing plasma chitotriosidase and the toxic metabolite lyso-Gb1 – key biomarkers of Gaucher disease – had both dropped sharply below the patient’s baseline levels achieved on enzyme replacement therapy (ERT) before gene therapy was administered. Additionally, all three cystinosis patients in the investigator-sponsored Phase 1/2 trial ii of AVR-RD-04 show strong data across multiple measures and remain off cysteamine pills and eye drops, with trial enrollment completion expected this year. “We are thrilled to begin the new year with this update, which adds to the breadth of strong clinical data we’ve reported across our leading lysosomal disorder pipeline of single-dose gene therapies,” said Geoff MacKay, president and CEO of AVROBIO. “With 13 patients dosed across three clinical programs, we have observed sustained and potentially transformative improvements in key biomarkers and functional metrics, with data from our Fabry disease program out 3 ½ years after dosing. Additionally, enrollment activities for our Fabry disease trial are accelerating, giving us added confidence in our efforts to meet our goal of having dosed a cumulative 30 patients across all our clinical programs by the end of the year. With this strong momentum, we look forward to clarifying the regulatory pathway with regulatory agencies.” The data will be presented this week at the 17 th annual WORLD Symposium ™, an annual scientific meeting dedicated to lysosomal disorders, held virtually Feb. 8-12, 2021. The presentations and posters are available online for WORLD attendees on the conference website. FAB-GT biopsy data: 100% reduction of kidney substrate at 12 months in first patient dosed with plato®gene therapy platform Gb3 is a fatty substrate that accumulates in the cells of Fabry disease patients and can result in damage to multiple organs, including the kidneys, heart and CNS. The kidney biopsy for Patient 4 in the Phase 2 trial showed a reduction from an average of 4.0 globotriaosylceramide (Gb3) inclusions per peritubular capillary (PTC) at baseline to zero inclusions per PTC one year after dosing, a 100% reduction ( p <0.0001). This assessment was made by two blinded pathologists who independently scored 99 digital images of the sectioned kidney from the 12-month biopsy. Every image scored zero inclusions. Patient 4 is the first in the trial treated using AVROBIO’s proprietary plato® gene therapy platform, which includes a state-of-the-art lentiviral vector, a personalized conditioning regimen with precision dosing and an automated, closed manufacturing process intended to deliver potent and consistent drug product from manufacturing sites worldwide at commercial scale. “The complete clearance of Gb3 substrate in kidney tissue, coming on top of strong results from the first evaluable kidney biopsy in this trial, is very exciting,” said Mark Thomas, M.D., the lead investigator in the FAB-GT trial, a clinician in the department of nephrology at Royal Perth Hospital and a clinical professor at the University of Western Australia Medical School. “Along with the reduction in plasma lyso-Gb3 observed across patients in this trial, which has been sustained up to 2.5 years so far, a massive drop in kidney substrate has the potential to substantially improve outcomes over ERT – the current standard of care. Fabry disease is a serious and life-shortening condition for many patients that requires lifelong fortnightly ERT infusions, with life-limiting symptoms manifesting throughout the body and brain, and we urgently need options to halt, prevent or reverse progression of the disease.” Two of four FAB-GT trial participants had evaluable kidney biopsies. As previously reported, the kidney biopsy for Patient 1 showed an 87% reduction, effective clearance of Gb3 inclusions per PTC compared to baseline. Additional Fabry disease clinical data: Continued durability across multiple biomarkers and functional cardiac measurements In addition to the kidney biopsy, AVROBIO reported updated data suggesting generally stable and sustained plasma and leukocyte alpha-galactosidase A (AGA) enzyme activity and a corresponding reduction in toxic plasma lyso-Gb3 in patients across the Phase 1 and FAB-GT trials of AVR-RD-01. To date, four patients have been dosed in the Phase 2 FAB-GT trial and five patients have been dosed in the fully enrolled Phase 1 trial. New aggregated data across all cardiac measures for the FAB-GT patients show patients continue to exhibit stable cardiac structure and function at 12 months post-gene therapy, which is notable given that people living with Fabry disease often experience progressive left ventricular hypertrophy and fibrosis, leading to reduced cardiac function. Additionally, the company is leveraging existing trial sites to potentially expand the pool of patients globally, with four Fabry disease patients from Brazil currently moving through the travel, screening, consent and enrollment process for potential treatment at AVROBIO’s global center of excellence in Australia. No unexpected safety events have been identified in the AVR-RD-01 Phase 1 and Phase 2 trials as of the safety data cut-off date of Nov. 26, 2020 and Dec. 7, 2020, respectively. Eight serious adverse events (SAEs) reported in the two Fabry disease trials have been consistent with the conditioning regimen, stem cell mobilization, underlying disease or pre-existing conditions. All SAEs have been resolved without clinical sequelae. Enrollment in the FAB-GT trial (NCT03454893) is ongoing, and further details are available on clinicaltrials.gov. Gaucher disease type 1: Preliminary clinical data in first patient show improvement in relevant biomarkers, plasma chitotriosidase and lyso-Gb1, over patient’s ERT baseline The first patient dosed in the Phase 1/2 Guard1 trial of AVR-RD-02 shows substantial improvement over pre-gene therapy ERT baseline in key biomarkers at six months post-gene therapy. This patient, who was previously ERT-stable, discontinued ERT use prior to gene therapy and remains off ERT. She was treated using AVROBIO’s proprietary plato® gene therapy platform. The patient’s plasma chitotriosidase levels dropped 49% from her pre-gene therapy ERT baseline levels. Plasma chitotriosidase is a biomarker of activated macrophages, which lead to chronic inflammation and severe organ damage. Six-month data show continued reduction in plasma chitotriosidase since the patient’s three-month exam, suggesting that healthy macrophages carrying the therapeutic gene may be replacing the diseased Gaucher cells. At six months post-gene therapy, the patient’s glucosylsphingosine (lyso-Gb1) metabolite levels were down 44% from her pre-gene therapy ERT baseline levels. As with chitotriosidase, the lyso-Gb1 levels were lower at six months than three months, suggesting continued improvement since dosing. Lyso-Gb1 is a toxic metabolite and a highly sensitive and specific biomarker for Gaucher disease. Elevated Lyso-Gb1 levels contribute to the severe organ damage commonly seen in Gaucher disease. Hemoglobin and platelet counts, which are typically low in patients with Gaucher disease, remained in the normal range for the first patient at six months post-gene therapy. “The early data from the first patient dosed with AVR-RD-02, our investigational gene therapy for Gaucher disease type 1, are consistent with what we have seen in our Fabry disease trials with lyso-Gb3,” said MacKay. “Based on the data observed to date, we believe lentiviral gene therapy drives down toxic metabolites below levels of ERT, supporting our view that gene therapy has the potential to prevent, halt or even reverse progression of these devastating diseases with a single infusion.” No unexpected safety events have been identified in this first patient. There have been no SAEs related to AVR-RD-02 as of the safety data cut-off date of Jan. 4, 2021. Adverse events (AEs) reported have been consistent with the conditioning regimen, stem cell mobilization, underlying disease or pre-existing conditions. Enrollment in the Phase 1/2 Guard1 trial (NCT04145037) is ongoing, and further details are available on clinicaltrials.gov. Cystinosis: Continued positive data across multiple measures;all three patients remain cysteamine-independent post-gene therapy All three cystinosis patients in the investigator-sponsored Phase 1/2 trial of AVR-RD-04 show strong data across multiple measures. Vector copy number (VCN/dg) data for all three patients continue to perform as expected. The first patient has potentially reached a VCN plateau, similar to the pattern seen in AVROBIO’s Fabry trials. The second patient had a VCN of 1.7/dg at six months and the third patient had a VCN of 2.6/dg at one month. All three patients remain off cysteamine pills and eye drops at 16, six and two months post-gene therapy respectively. The renal function data for the first patient dosed in the trial, who has established, progressive kidney disease, suggest continued stabilization post-gene therapy. Additionally, imaging scans show a marked reduction in crystal density in both corneas, as well as a two-grade clinically meaningful improvement (from grade 3 to grade 1) in his photophobia, one of the more debilitating effects of cystinosis. Photophobia can be extremely painful for patients exposed to any level of light, requiring some patients to wear dark glasses all the time, even at night. The investigator-sponsored Phase 1/2 trial (NCT03897361) of AVR-RD-04 is expected to be fully enrolled this year. Further details are available on clinicaltrials.gov. No unexpected safety events have been identified in the trial, with no SAEs reported as of the Jan. 27, 2021, safety data cut-off date. AEs reported have been consistent with the conditioning regimen, stem cell mobilization, underlying disease or pre-existing conditions. Investor and analyst presentation today at 8 a.m. ET The conference call and presentation will begin at 8:00 a.m. ET and can be accessed under “Events and Presentations” in the Investors section of the company’s website at avrobio.com or by dialing (866) 353-0165 from locations in the U.S. and (409) 217-8080 from outside the U.S. The conference ID number is 3287052. An archived webcast recording of the event will be available on the website for approximately 30 days. About AVROBIO Our vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of therapeutic protein, even in hard-to-reach tissues and organs including brain, muscle and bone. Our ex vivo lentiviral gene therapy pipeline includes clinical programs in Fabry disease, Gaucher disease type 1 and cystinosis, as well as preclinical programs in Hunter syndrome, Gaucher disease type 3 and Pompe disease. AVROBIO is powered by our industry leading plato® gene therapy platform, our foundation designed to deliver gene therapy worldwide. We are headquartered in Cambridge, Mass., with an office in Toronto, Ontario. For additional information, visit avrobio.com, and follow us on Twitter and LinkedIn. Forward-Looking Statement This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “aims,” “anticipates,” “believes,” “could,” “designed to,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words and phrases or similar expressions that are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding our business strategy for and the potential therapeutic benefits of our prospective product candidates, results of preclinical studies, the design, commencement, enrollment and timing of ongoing or planned clinical trials, clinical trial results, product approvals and regulatory pathways, the timing of patient recruitment and enrollment activities, and product approvals, anticipated benefits of our gene therapy platform including potential impact on our commercialization activities, timing and likelihood of success, and the expected benefits and results of our implementation of the plato® platform in our clinical trials and gene therapy programs, including the use of a personalized and ultra-precision busulfan conditioning regimen. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Results in preclinical or early-stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented. Any forward-looking statements in this press release are based on AVROBIO’s current expectations, estimates and projections about our industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of AVROBIO’s product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any ongoing or planned clinical trials of AVROBIO or our collaborators, the risk that AVROBIO may not successfully recruit or enroll a sufficient number of patients for our clinical trials, the risk that AVROBIO may not realize the intended benefits of our gene therapy platform, including the features of our plato® platform, the risk that our product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate, the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or trials involving AVROBIO’s product candidates, the risk that we will be unable to obtain and maintain regulatory approval for our product candidates, the risk that the size and growth potential of the market for our product candidates will not materialize as expected, risks associated with our dependence on third-party suppliers and manufacturers, risks regarding the accuracy of our estimates of expenses and future revenue, risks relating to our capital requirements and needs for additional financing, risks relating to clinical trial and business interruptions resulting from the COVID-19 outbreak or similar public health crises, including that such interruptions may materially delay our enrollment and development timelines and/or increase our development costs or that data collection efforts may be impaired or otherwise impacted by such crises, and risks relating to our ability to obtain and maintain intellectual property protection for our product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause AVROBIO’s actual results to differ materially and adversely from those contained in the forward-looking statements, see the section entitled “Risk Factors” in AVROBIO’s most recent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties and other important factors in AVROBIO’s subsequent filings with the Securities and Exchange Commission. AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. i Formerly known as the FAB-201 trial ii Collaborator-sponsored Phase 1/2 clinical trial of AVR-RD-04 is funded in part by grants to UCSD from the California Institute for Regenerative Medicine (CIRM), Cystinosis Research Foundation (CRF) and National Institutes of Health (NIH). View source version on businesswire.com:https://www.businesswire.com/news/home/20210208005145/en/ CONTACT: Investor: Christopher F. Brinzey Westwicke, an ICR Company 339-970-2843 [email protected] Media: Stephanie Simon Ten Bridge Communications 617-581-9333 [email protected] KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: RESEARCH FDA GENETICS CLINICAL TRIALS BIOTECHNOLOGY OTHER HEALTH HEALTH OTHER SCIENCE SCIENCE SOURCE: AVROBIO, Inc. Copyright Business Wire 2021. PUB: 02/08/2021 07:00 AM/DISC: 02/08/2021 07:01 AM http://www.businesswire.com/news/home/20210208005145/en Facebook Previous articleIntroducing Ring Video Doorbell Pro 2, Ring’s Most Advanced Wired Doorbell Featuring 3D Motion Detection and Bird’s Eye ViewNext articleNew pups hit the dog park; owners are nervous wrecks Digital AIM Web Support Pinterest WhatsApp Twitter
Cook County Illinois Equity Stripping Fair Housing Act Lawsuits Wells Fargo 2014-12-03 Brian Honea Subscribe Demand Propels Home Prices Upward 2 days ago Share Save Servicers Navigate the Post-Pandemic World 2 days ago Cook County, Illinois, Sues Lender Over Alleged Predatory Practices December 3, 2014 698 Views Governmental Measures Target Expanded Access to Affordable Housing 2 days ago Home / Daily Dose / Cook County, Illinois, Sues Lender Over Alleged Predatory Practices Governmental Measures Target Expanded Access to Affordable Housing 2 days ago Servicers Navigate the Post-Pandemic World 2 days ago Cook County, Illinois, home of the third most populated city in the U.S., has filed a lawsuit against Wells Fargo, accusing the nation’s largest residential mortgage lender of predatory lending practices.The complaint filed by Cook County, which is home to Chicago and has a population of about five million, accuses Wells Fargo of violating the Fair Housing Act by engaging in a practice known as “equity stripping.” The county alleges that Wells Fargo targeted minorities, particularly Latinos and African-Americans, for high-cost mortgage loans in order to maximize the bank’s profits and assets without regard to the borrower’s ability to repay the loan.The county alleges in the complaint that this practice led to a large number of foreclosures in the area, which in turn contributed to the spreading of blight. The complaint says that as many as 26,000 loans may have been affected. The county is believed to be seeking more than $300 million in damages in addition to a court order that requires Wells Fargo to stop the alleged predatory lending practice.”The county’s accusations are baseless and it’s disappointing they chose to pursue a lawsuit against Wells Fargo rather than collaborate together to help borrowers and home owners in the county,” Wells Fargo spokesman Tom Goyda said in an email. “Wells Fargo’s team members live and work in the Chicago area and we stand behind our record as a fair and responsible lender, which includes an $8.2 million down payment assistance grant program that helped create 547 new homeowners in Chicago and the Cook County suburbs over the past two years. We will vigorously defend ourselves and continue to focus on helping customers succeed financially and expanding homeownership in Illinois and across the United States.”Similar lawsuits have been filed against Wells Fargo in the last year by Los Angeles and Miami in regards to the bank’s mortgage lending practices. The Miami suit was dismissed in July and is being appealed, while Wells Fargo lost a bid for the dismissal of the Los Angeles suit. Sign up for DS News Daily The Best Markets For Residential Property Investors 2 days ago Demand Propels Home Prices Upward 2 days ago Data Provider Black Knight to Acquire Top of Mind 2 days ago Brian Honea’s writing and editing career spans nearly two decades across many forms of media. He served as sports editor for two suburban newspaper chains in the DFW area and has freelanced for such publications as the Yahoo! Contributor Network, Dallas Home Improvement magazine, and the Dallas Morning News. He has written four non-fiction sports books, the latest of which, The Life of Coach Chuck Curtis, was published by the TCU Press in December 2014. A lifelong Texan, Brian received his master’s degree from Amberton University in Garland. About Author: Brian Honea The Week Ahead: Nearing the Forbearance Exit 2 days ago Related Articles Data Provider Black Knight to Acquire Top of Mind 2 days ago Tagged with: Cook County Illinois Equity Stripping Fair Housing Act Lawsuits Wells Fargo The Best Markets For Residential Property Investors 2 days ago Previous: Shapiro & Zielke Raises $10K for Local Charity 360 Communities Next: Fed Reports Continued Growth In Final Beige Book of 2014 in Daily Dose, Featured, Foreclosure, News Print This Post